345 related articles for article (PubMed ID: 32634212)
1. Clinical Practice of Adalimumab and Infliximab Biosimilar Treatment in Adult Patients With Crohn's Disease.
Reinisch W; Gecse K; Halfvarson J; Irving PM; Jahnsen J; Peyrin-Biroulet L; Rogler G; Schreiber S; Danese S
Inflamm Bowel Dis; 2021 Jan; 27(1):106-122. PubMed ID: 32634212
[TBL] [Abstract][Full Text] [Related]
2. Predictors of anti-TNF treatment failure in anti-TNF-naive patients with active luminal Crohn's disease: a prospective, multicentre, cohort study.
Kennedy NA; Heap GA; Green HD; Hamilton B; Bewshea C; Walker GJ; Thomas A; Nice R; Perry MH; Bouri S; Chanchlani N; Heerasing NM; Hendy P; Lin S; Gaya DR; Cummings JRF; Selinger CP; Lees CW; Hart AL; Parkes M; Sebastian S; Mansfield JC; Irving PM; Lindsay J; Russell RK; McDonald TJ; McGovern D; Goodhand JR; Ahmad T;
Lancet Gastroenterol Hepatol; 2019 May; 4(5):341-353. PubMed ID: 30824404
[TBL] [Abstract][Full Text] [Related]
3. Comparative efficacy and safety of biologic therapies for moderate-to-severe Crohn's disease: a systematic review and network meta-analysis.
Singh S; Murad MH; Fumery M; Sedano R; Jairath V; Panaccione R; Sandborn WJ; Ma C
Lancet Gastroenterol Hepatol; 2021 Dec; 6(12):1002-1014. PubMed ID: 34688373
[TBL] [Abstract][Full Text] [Related]
4. Cost-Effectiveness Comparison of Ustekinumab, Infliximab, or Adalimumab for the Treatment of Moderate-Severe Crohn's Disease in Biologic-Naïve Patients.
Aliyev ER; Hay JW; Hwang C
Pharmacotherapy; 2019 Feb; 39(2):118-128. PubMed ID: 30565265
[TBL] [Abstract][Full Text] [Related]
5. Enhancing treatment success in inflammatory bowel disease: Optimising the use of anti-TNF agents and utilising their biosimilars in clinical practice.
Armuzzi A; Bouhnik Y; Cummings F; Bettey M; Pieper B; Kang T
Dig Liver Dis; 2020 Nov; 52(11):1259-1265. PubMed ID: 32601035
[TBL] [Abstract][Full Text] [Related]
6. Tumor necrosis factor-alpha antibody for maintenance of remission in Crohn's disease.
Behm BW; Bickston SJ
Cochrane Database Syst Rev; 2008 Jan; (1):CD006893. PubMed ID: 18254120
[TBL] [Abstract][Full Text] [Related]
7. Systematic review and network meta-analysis: first- and second-line biologic therapies for moderate-severe Crohn's disease.
Singh S; Fumery M; Sandborn WJ; Murad MH
Aliment Pharmacol Ther; 2018 Aug; 48(4):394-409. PubMed ID: 29920733
[TBL] [Abstract][Full Text] [Related]
8. Efficacy, tolerability, and safety of infliximab biosimilar in comparison to originator biologic and adalimumab in patients with Crohn disease.
Kaniewska M; Rosołowski M; Rydzewska G
Pol Arch Intern Med; 2019 Aug; 129(7-8):484-489. PubMed ID: 31316042
[TBL] [Abstract][Full Text] [Related]
9. Experience With Anti-TNF-α Biologic Agents in Succession in Patients With Crohn's Disease: A Retrospective Analysis of a Single Center.
Ferges W; Rampertab SD; Shafqet M; Salimi Q; You G; Yousefzadeh E; Cheng JQ; Das KM
J Clin Gastroenterol; 2016 Apr; 50(4):326-30. PubMed ID: 25984976
[TBL] [Abstract][Full Text] [Related]
10. A systematic review and economic evaluation of the use of tumour necrosis factor-alpha (TNF-α) inhibitors, adalimumab and infliximab, for Crohn's disease.
Dretzke J; Edlin R; Round J; Connock M; Hulme C; Czeczot J; Fry-Smith A; McCabe C; Meads C
Health Technol Assess; 2011 Feb; 15(6):1-244. PubMed ID: 21291629
[TBL] [Abstract][Full Text] [Related]
11. Comparative Efficacy of Biologic Therapies for Inducing Response and Remission in Fistulizing Crohn's Disease: Systematic Review and Network Meta-Analysis of Randomized Controlled Trials.
Shehab M; Alrashed F; Heron V; Restellini S; Bessissow T
Inflamm Bowel Dis; 2023 Mar; 29(3):367-375. PubMed ID: 35604382
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of Infliximab in Crohn's Disease Patients with Prior Primary-Nonresponse to Tumor Necrosis Factor Antagonists.
Clark-Snustad KD; Singla A; Lee SD
Dig Dis Sci; 2019 Jul; 64(7):1952-1958. PubMed ID: 30815825
[TBL] [Abstract][Full Text] [Related]
13. Long-term outcomes of patients with Crohn's disease who received infliximab or adalimumab as the first-line biologics.
Inokuchi T; Takahashi S; Hiraoka S; Toyokawa T; Takagi S; Takemoto K; Miyaike J; Fujimoto T; Higashi R; Morito Y; Nawa T; Suzuki S; Nishimura M; Inoue M; Kato J; Okada H
J Gastroenterol Hepatol; 2019 Aug; 34(8):1329-1336. PubMed ID: 30724387
[TBL] [Abstract][Full Text] [Related]
14. Infliximab Originator, Infliximab Biosimilar, and Adalimumab Are More Effective in Crohn's Disease Than Ulcerative Colitis: A Real-Life Cohort Study.
Barberio B; Zingone F; D'Incà R; Rovigo L; Bertani L; Bodini G; Ghisa M; Gubbiotti A; Massimi D; Lorenzon G; Savarino EV
Clin Transl Gastroenterol; 2020 May; 11(5):e00177. PubMed ID: 32677808
[TBL] [Abstract][Full Text] [Related]
15. Safety and efficacy of BI 695501 versus adalimumab reference product in patients with advanced Crohn's disease (VOLTAIRE-CD): a multicentre, randomised, double-blind, phase 3 trial.
Hanauer S; Liedert B; Balser S; Brockstedt E; Moschetti V; Schreiber S
Lancet Gastroenterol Hepatol; 2021 Oct; 6(10):816-825. PubMed ID: 34388360
[TBL] [Abstract][Full Text] [Related]
16. Comparative safety and effectiveness of vedolizumab to tumour necrosis factor antagonist therapy for Crohn's disease.
Bohm M; Xu R; Zhang Y; Varma S; Fischer M; Kochhar G; Boland B; Singh S; Hirten R; Ungaro R; Shmidt E; Lasch K; Jairaith V; Hudesman D; Chang S; Lukin D; Swaminath A; Sands BE; Colombel JF; Kane S; Loftus EV; Shen B; Siegel CA; Sandborn WJ; Dulai PS;
Aliment Pharmacol Ther; 2020 Aug; 52(4):669-681. PubMed ID: 32656800
[TBL] [Abstract][Full Text] [Related]
17. Use of Infliximab Biosimilar Versus Originator in a Pediatric United Kingdom Inflammatory Bowel Disease Induction Cohort.
Chanchlani N; Mortier K; Williams LJ; Muhammed R; Auth MKH; Cosgrove M; Fagbemi A; Fell J; Chong S; Zamvar V; Hyer W; Bisset WM; Morris MA; Rodrigues A; Mitton SG; Bunn S; Beattie RM; Willmott A; Wilson DC; Russell RK
J Pediatr Gastroenterol Nutr; 2018 Oct; 67(4):513-519. PubMed ID: 29697550
[TBL] [Abstract][Full Text] [Related]
18. Review article: pharmacological aspects of anti-TNF biosimilars in inflammatory bowel diseases.
Papamichael K; Van Stappen T; Jairath V; Gecse K; Khanna R; D'Haens G; Vermeire S; Gils A; Feagan BG; Levesque BG; Vande Casteele N
Aliment Pharmacol Ther; 2015 Nov; 42(10):1158-69. PubMed ID: 26365281
[TBL] [Abstract][Full Text] [Related]
19. Management of inflammatory bowel disease with infliximab and other anti-tumor necrosis factor alpha therapies.
Magro F; Portela F
BioDrugs; 2010 Dec; 24 Suppl 1():3-14. PubMed ID: 21175228
[TBL] [Abstract][Full Text] [Related]
20. Magnetic resonance enterography changes after antibody to tumor necrosis factor (anti-TNF) alpha therapy in Crohn's disease: correlation with SES-CD and clinical-biological markers.
Stoppino LP; Della Valle N; Rizzi S; Cleopazzo E; Centola A; Iamele D; Bristogiannis C; Stoppino G; Vinci R; Macarini L
BMC Med Imaging; 2016 May; 16(1):37. PubMed ID: 27149857
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
